Solving the Rare Disease Paradox: Putting Patients at the Center of Clinical Research

The harsh reality of drug development is that the majority of new therapies never make it to market. In non-oncology, less than 1 in 10 investigational products successfully navigate from Phase I through regulatory approval. But for the ~300 million people globally living with rare conditions, these are more than statistics; they're missed opportunities for life-saving care.

Your organization is likely facing the same formidable challenges. Rare disease trials deal with small, dispersed patient populations. You're trying to find a needle in a global haystack while balancing the ethical implications of traditional placebo control arms for life-threatening illnesses. Standard trial protocols simply don't translate to these unique needs.

To find treatments for the 95% of rare diseases that currently have no approved options, we must rethink how we recruit, retain, and respect the patients who volunteer for these studies.

The Recruitment Gap: Finding the Hidden Patient

Recruiting the right patients faster is the first hurdle in any efficient trial. But in the rare disease space, patient populations are often disparate and scattered across the globe. This makes targeted recruitment labor-intensive and difficult.

When you fail to reach these patients, you aren't just missing data, you're creating disparities in care. For many, a clinical trial is the only viable treatment path. Inadequate recruitment risks collecting incomplete or inaccurate results, which holds back progress for everyone.

“Around 95% of rare diseases have no approved treatment options, and clinical trials are often the only viable treatment.”

– Ruthie Davi, VP of Statistics and Regulatory Innovation, Medidata, Dassault Systèmes

You can now use predictive analytics of large, external data sets to identify high-priority sites for recruitment. Instead of guessing where patients are, you can use data to reach those most suitable for enrollment. High-performing sites identified through these methods enroll patients an average of 5 times faster than low performers. This not only helps your timelines, but also gets treatments into the hands of patients sooner.

The Retention Crisis: Reducing Patient Burden

Once you enroll a patient, their end-to-end experience determines whether they stay. Rare disease trials are often more demanding, leading to high drop-out rates and a significant personal toll on participants.

Traditional on-site interactions are time-intensive and financially burdensome for families who must travel long distances. This is often inevitable due to the scattered nature of these populations. Further, complex, paper-based consenting processes can feel overwhelming. So how do we make participation easier?

Decentralization is the key to widening access. By adopting tools like wearable health trackers and scheduling video calls instead of face-to-face consultations, you remove the travel barrier. When a trial includes remote elements, the decision to participate becomes much easier for patients who live far from a site. It's about meeting patients where they are—not forcing them to come to you.

The Ethics of Design: Moving Beyond Placebos

The need for control arms is often the biggest deterrent for rare disease participants. Traditional designs require one-third to one-half of participants to receive a placebo. For a child with a life-threatening condition, being assigned to a control group can be devastating for the family and often leads to early discontinuation from the trial.

With an estimated 85%–90% of rare disease cases being serious or life-threatening, the use of a placebo can raise ethical concerns.

Medidata Synthetic Control Arm® (SCA) provides a robust, regulatory-grade alternative. By using historical data from previous trials and real-world data, we create a "Virtual Twin" to compare against the treatment data.

“SCAs provide a robust, regulatory-grade alternative to traditional clinical trial designs, offering significant impact within rare or biomarker-driven populations where unmet medical need and patient recruitment are persistent barriers to progress.”

– Ruthie Davi

This approach means a larger portion of patients enrolled in your trial actually receive the study drug. It speeds up recruitment, increases retention, and helps patients gain access to life-changing therapies faster.

Design for Certainty

Medidata’s unified platform is purpose-built to help you design smarter protocols and streamline execution. Whether you're using Medidata Synthetic Control Arm® to reduce control sample sizes or Medidata eCOA to ease the burden on participants, our goal is the same: to help you bring the right treatments to the right people—at the right time.

By turning your study protocol into a digital artifact, you can benchmark complexity and optimize eligibility criteria. You can save roughly 70% of the time typically spent on budget building and reduce database build times from months to weeks.

The progress made in digitalization and AI is promising, but there’s more work to do. It's time to lead with innovation for the benefit of a population that has historically been overlooked.

Read the full article from Medidata's Ruthie Davi in Clinical Trials Arena.